Although the cytoplasmic domain of the human Fc␥RIa ␣-chain lacks tyrosine-based phosphorylation motifs, it modulates receptor cycling and receptorspecific cytokine production. The cytoplasmic domain of Fc␥RIa is constitutively phosphorylated, and the inhibition of dephosphorylation with okadaic acid, an inhibitor of type 1 and type 2A protein serine/threonine phosphatase, inhibits both receptor-induced activation of the early tyrosine phosphorylation cascade and receptor-specific phagocytosis. To explore the basis for these effects of the cytoplasmic domain of Fc␥RIa, we developed a series of human Fc␥RIa molecular variants, expressed in the murine macrophage cell line P388D1, and demonstrate that serine phosphorylation of the cytoplasmic domain is an important regulatory mechanism. Truncation of the cytoplasmic domain and mutation of the cytoplasmic domain serine residues to alanine abolish the okadaic acid inhibition of phagocytic function. In contrast, the serine mutants did not recapitulate the selective effects of cytoplasmic domain truncation on cytokine production. These results demonstrate for the first time a direct functional role for serine phosphorylation in the ␣-chain of Fc␥RIa and suggest that the cytoplasmic domain of Fc␥RI regulates the different functional capacities of the Fc␥RIa-receptor complex.The ␥-chain, initially described as a component of the Fc⑀RI signaling complex, is able to form multichain complexes with the ligand-binding ␣-chain of several Fc receptors (1-3). The Fc␥RIa (CD64), Fc␥RIIIa (CD16A), Fc␣RI (CD89), and Fc⑀RI ␣-chains associate with the ␥-chain as a common molecule in signal transduction. The stoichiometry of the assembly of the receptor complex is generally ␣␥ 2 , except in mast cells, which may have Fc⑀RI and Fc␥RIIIa complexes where there is, in addition, a  chain (␣␥ 2 ) (4 -6). In all of these Fc receptor complexes, the ␥-chain with its tyrosine activation motif (ITAM) is necessary for receptor signaling (7-9). In the case of Fc⑀RI, the -chain serves as an amplifier of receptor function (10, 11).Fc␥RIa, a receptor with high affinity for IgG (10 9 M Ϫ1 ) (12), has received attention over the past few years as a potential therapeutic target in malignancy. Targeting of tumors to Fc␥RI with bispecific mAbs 1 can facilitate tumor killing via Fc␥RI-expressing macrophages, and therapeutic humanized bispecific reagents targeting human Fc␥RIa are currently in clinical trials (13-19). Bispecific mAb-based antigen targeting to Fc␥RI can also enhance antigen presentation by dendritic cells with clear applications to enhanced immunization strategies (20).Expression of the Fc␥RIa ␣-chain in the presence or absence of the ␥-chain has allowed an assessment of the functional capacity of each chain. For example, the ␥-chain is necessary for Fc␥RIa-mediated phagocytosis and Fc␥RIa-induced activation of tyrosine kinase activity (7-9). However, the ␣-chain is sufficient for endocytosis (7,9). Whereas expression of the Fc␥RIa ␣-chain without a CY domain can also induce pseudopod ext...